Directorio
We are doing this study to find out if an investigational drug called OBI-3424 is a safe and effective option for patients with leukemia or lymphoma.
We are doing this study to find out if either of 2 different, experimental drug regimens (ramucirumab plus paclitaxel or FOLFIRI) is an option for treating small bowel cancer that has not responded to therapy.
We are doing this study to compare the early treatment (before you have cancer symptoms) of Venetoclax and Obitnutuzumab (V-O) to the usual treatment of V-O after you have cancer symptoms. This study will help doctors figure out if early treatment is better, the same, or worse than the usual approach of waiting until the patient has cancer symptoms before starting treatment.
We are doing this study to find out if either of two experimental drugs (mosunetuzumab and polatuzumab vedotin) is a safe and effective option for people who have had CAR T-cell therapy. We want to know how each drug works on its own as well as in combination with each other when given after CAR T-cell therapy is complete.
We are doing this study to compare two treatment options for PRCC. We want to know if adding an experimental drug called atezolimumab (the study drug) to the typical drug used in PRCC treatment, cabozantinib, can improve outcomes or extend survival time.
We are doing this study to find out if a pair of investigational drugs called ramucirumab and pembrolizumab (the study drugs) are a safe and effective treatment for your form of cancer. We want to know how well the study drugs work in comparison to the standard treatment for Stage IV or recurrent NSCLC.
We are doing this study to find out the effects, good or bad, of an investigational drug called RO7200220 (the study drug) for participants with uveitic macular edema. This condition is caused by uveitis, and it is when fluid builds up in the retinal layers and causes swelling that can impair vision.
We are doing this study to look at different tissues that could contribute to chronic pain and obesity.